In an exciting development for pediatric medicine and global health, Valneva SE’s VLA1553 vaccine has demonstrated promising results in pediatric trials, highlighting its potential to significantly reduce the burden of the virulent Chikungunya virus. The vaccine evoked robust immune responses in children up to 180 days post-vaccination, a scientific feat which marks a significant stride […]